Glucotrack (GCTK) cancels special meeting; only 17.6% turnout

Q: How many shares were eligible to vote for GCTK?

There were 158,370 shares of common stock outstanding and entitled to vote as of September 23, 2025.

Q: What percentage of shares were represented at the reconvened meeting?

17.6% of eligible shares were represented in person or by proxy.

Q: When did the Glucotrack special meeting occur?

It was originally convened on October 31, 2025 and reconvened on November 7, 2025.

Glucotrack, Inc. permanently adjourned and cancelled its special stockholder meeting after failing to reach a quorum when it reconvened on November 7, 2025.

Filing Impact

(Moderate)

Filing Sentiment

(Neutral)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Form Type

8-K

Rhea-AI Filing Summary

Glucotrack, Inc. permanently adjourned and cancelled its special stockholder meeting after failing to reach a quorum when it reconvened on November 7, 2025. The meeting was originally convened on October 31, 2025 and adjourned due to the absence of a quorum.

As of the September 23, 2025 record date, 158,370 shares of common stock were outstanding and entitled to vote, and 17.6% of those shares were represented in person or by proxy at the reconvened meeting, which did not constitute a quorum under the company’s bylaws. No business was conducted.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Glucotrack (GCTK) disclose in this 8-K?

The company cancelled its special stockholder meeting after the reconvened session on November 7, 2025 failed to reach a quorum.

How many shares were eligible to vote for GCTK?

There were 158,370 shares of common stock outstanding and entitled to vote as of September 23, 2025.

What percentage of shares were represented at the reconvened meeting?

17.6% of eligible shares were represented in person or by proxy.

Was any business conducted at the Glucotrack special meeting?

No. The meeting lacked a quorum under the company’s bylaws and was permanently adjourned and cancelled.

When did the Glucotrack special meeting occur?

It was originally convened on October 31, 2025 and reconvened on November 7, 2025.

What is the impact on Glucotrack’s proposals or agenda items?

No items were considered because the meeting did not achieve a quorum; no business was conducted.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding 8-K Material Events →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Accepted by SEC EDGAR 11/07/2025 - 05:15 PM

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): November 7, 2025

GLUCOTRACK, INC.

(Exact name of registrant as specified in its charter)

Delaware	001-41141	98-0668934
(State or Other Jurisdiction	(Commission	(IRS Employer
of Incorporation)	File Number)	Identification No.)

301 Rte. 17 North, Ste. 800, Rutherford, NJ		07070
(Address of principal executive offices)		(Zip Code)

Registrant’s telephone number, including area code: (201) 842-7715

N/A

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common Stock, par value $0.001 per share		GCTK		The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR § 230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR § 240.12b-2).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 5.07. Submission of Matters to a Vote of Security Holders.

As previously disclosed, the special meeting of stockholders (the “Meeting”) of Glucotrack, Inc. (the “Company”) was originally convened on October 31, 2025 and adjourned due to the absence of a quorum. The Meeting reconvened on November 7, 2025. As of the close of business on September 23, 2025, the record date for the Meeting, there were 158,370 shares of common stock outstanding and entitled to vote, 17.6% of which shares were represented in person or by proxy at the reconvened meeting, which did not constitute a quorum under the Company’s bylaws. Accordingly, the Meeting was permanently adjourned and cancelled due to lack of a quorum, and no business was conducted.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: November 7, 2025

	GLUCOTRACK, INC.

	By:	/s/ Paul Goode
	Name:	Paul Goode
	Title:	Chief Executive Officer

Source: View Original Filing on SEC EDGAR